Patents by Inventor Shuren Liao

Shuren Liao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACOLOGIC APPROACH FOR SUPPRESSION OF CORONAVIRUSES
    Publication number: 20240009221
    Abstract: Compositions for prevention or treatment for the SARS family of coronaviruses, e.g., SARS-CoV-2 and SARS-OC43 (common cold virus), include non-nucleoside reverse transcriptase inhibitors (NNRTI), such as rilpivirine, and nucleoside-analogue antiviral agents, such as remdesivir.
    Type: Application
    Filed: April 14, 2023
    Publication date: January 11, 2024
    Inventors: Kamel Khalili, Shuren Liao, Ilker K. Sariyer
  • GENETIC APPROACH TO SUPPRESS CORONAVIRUSES
    Publication number: 20230390367
    Abstract: Compositions include gene editing agents, e.g. CRISPR that employ Cas13a for editing and inactivating sequences in the Coronavirus genome.
    Type: Application
    Filed: October 19, 2021
    Publication date: December 7, 2023
    Inventors: Kamel Khalili, Rafal Kaminski, Shuren Liao
  • Methods for enriching gene-targeted cells
    Patent number: 10724051
    Abstract: A gene of interest and the gene encoding hypoxanthine-aminopterin-thymidine (HPRT) can be co-targeted for Casp9 nuclease-mediated editing or alteration in a cell. Based on whether the HPRT gene is altered to encode a non-functional protein, or is not so-altered, the co-targeted cells can be selected and counter-selected. HPRT co-targeting can be used to sequentially disrupt as many genes of interest as cell viability permits.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: July 28, 2020
    Assignee: Institute For Cancer Research
    Inventors: Hong Yan, Shuren Liao
  • Methods For Enriching Gene-Targeted Cells
    Publication number: 20180100167
    Abstract: A gene of interest and the gene encoding hypoxanthine-aminopterin-thymidine (HPRT) can be co-targeted for Casp9 nuclease-mediated editing or alteration in a cell. Based on whether the HPRT gene is altered to encode a non-functional protein, or is not so-altered, the co-targeted cells can be selected and counter-selected. HPRT co-targeting can be used to sequentially disrupt as many genes of interest as cell viability permits.
    Type: Application
    Filed: October 6, 2017
    Publication date: April 12, 2018
    Inventors: Hong Yan, Shuren Liao